The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
PfizerForAll works within the existing healthcare system and through a growing network of partners to simplify access via established channels and to close gaps in care
e brings over 27+ years of rich pharmaceutical experience
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
Subscribe To Our Newsletter & Stay Updated
